The bioassay development cycle can be a long and winding road, with vital decisions at every stage of the process. Choosing the wrong path can mean hours of wasted effort and vast amounts of unncessary spending, while prudent choices can lead to an optimal assay, saving you time and money.
That’s why we’ve teamed up with RoukenBio to create a blog series with a detailed focus on the key decisions along the road to a successful bioassay. RoukenBio are a leading immunology Contract Research Organisation (CRO) based in Motherwell, Scotland with a mission to facilitate breakthrough discoveries. Drawing on their immuno-oncology expertise, RoukenBio has built up an array of assay systems to recreate immune cell interactions in the tumour microenvironment, intended to be as faithful to the physiological processes they are emulating as possible. With a strong focus on novel and emerging therapeutic classes that are designed to modulate these processes, their assay platforms are applicable to oncology, auto-immunity, inflammatory disease and beyond.
By combining RoukenBio’s experience working in the lab designing high-quality assay systems with Quantics’ 20+ years of work in bioassay statistical analysis, we will provide insight into full bioassay development process, helping you make the decsions which lead to an optimised bioassay.
The first part of our series, Potency Assays: The Cornerstone of Biotherapeutic Development, provides an overview of a bioassay system, it’s uses and overall goals, and the desirable characteristics which the development process looks to optimise. You can read the full blog at the link below.
Comments are closed.